

Newer approaches to the discovery of glitazones

Praveen Thaggikuppe Krishnamurthy

JSS College of Pharmacy, India

Abstract

Thiazolidines (TZDs) or glitazones are one of the important classes of insulin sensitizers used in the management of type 2 diabetes mellitus. These agents, however, suffer from some serious side effects such as fluid retention, weight gain, congestive heart failure, bone fracture and possibly bladder cancer, which resulted in their withdrawal from clinical use. The TZDs that were withdrawn from the clinical use were developed at the time when enough scientific data were not available on the structure and the transcriptional mechanisms of peroxisome proliferator activated receptors (PPARs). Recent advances in the understanding the structure and function of PPARs, however, have led to more rationalized approaches to develop these agents. This presentation discusses the various approaches that have been made to develop newer glitazones devoid of the problems associated with current TZDs. These approaches are based on the structural considerations of both the ligands and the receptors and also on the profile alterations of the ligands.

Biography

Dr. Praveen T.K. has completed his PhD from The Tamil Nadu Dr. M.G.R. Medical University, Chennai. He is working as Assistant Professor in the Dept. of Pharmacology at JSS College of Pharmacy, Ootacamund. Before this he worked as Research Associate at R&D centre, The Himalaya Drug Company, Bengaluru, India. He has published more than 14 papers in reputed journals and a book chapter. He is serving as an editorial board member for 3 reputed Journals. He has one ongoing research project as a Co-investigator from UGC, New Delhi. He has filed an Indian patent on "Novel Glitazones as PPAR alpha and PPAR gamma agonists and alpha glucosidase inhibitors".